Law T M, Ilson D H, Motzer R J
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Invest New Drugs. 1994;12(2):143-5. doi: 10.1007/BF00874445.
Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity. Eighty percent (12 of 15) of patients experienced grade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma.
15例晚期肾细胞癌患者参加了拓扑替康的II期临床试验。14例可评估患者中无一例达到完全或部分缓解。骨髓抑制是最常见的毒性反应。80%（15例中的12例）的患者出现III级或IV级中性粒细胞减少和/或贫血。拓扑替康对晚期肾细胞癌治疗无效。
